

LIFE SCIENCE TREND ANALYSIS

NETHERLANDS | 2026

**BIOTECH
GATE** 
BUSINESS DEVELOPMENT
DATABASE




VENTURE VALUATION
GLOBAL VALUATION SERVICES



hollandbio

APRIL 2026



ABOUT US



The following statistical information has been obtained from **Biotechgate**, a global, comprehensive life science database encompassing the biotechnology, pharmaceutical and medical device industries.

www.biotechgate.com



The Dutch Life Sciences Database is a part of the global Biotechgate and is brought to you in partnership with **Hollandbio**.

www.dutchlifescience.com



Biotechgate is owned and operated by **Venture Valuation AG**, a Zurich based company specializing in independent assessment and valuation of technology-driven companies in high growth industries, such as the life sciences (biotech, pharma, medtech), ICT, high-tech, nanotech, cleantech and renewable energy.

www.venturevaluation.com

OUR PARTNER

hollandbio



Hollandbio connects, supports, and represents over 270 medical, agro-food, and industrial biotech companies. Their members are active in all phases of research and development and include all company sizes: start-ups, SMEs, listed companies and multinationals.

Together, they strive for a society taking full advantage of the power of biotechnology in health, food and sustainability.

Explore the [hollandbio life Science Database](#) run by Biotechgate, which shows the Netherland's vibrant, dense biotechnology cluster of nearly 2000 life sciences companies and research organizations, all within a 120-mile radius.

OVERVIEW OF THE LIFE SCIENCE INDUSTRY



NUMBER OF COMPANIES BY SECTOR



For the definition of categories please visit www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html. Biotech Companies include the following categories: Biotechnology – Therapeutics and Diagnostics; Biotechnology – R&D; Biotechnology – Other. *Other life science related companies include supplier & engineering, professional services & consulting, media and public / non-profit organizations / medical facilities. Professional services & consulting includes 6 companies of the category "Media". Percentage value is expressed as % of total number of companies. Information displayed may alter as new information is received continuously


OVERVIEW OF BIOTECH COMPANIES

NUMBER OF COMPANIES BY SECTOR



BIOTECH – THERAPEUTICS & DIAGNOSTICS COMPANIES BY KEY ACTIVITIES


AS PERCENTAGE OF TOTAL NUMBER OF BIOTECH - THERAPEUTICS COMPANIES



For 178 Biotech Therapeutics companies there were 304 subsectors (key activity areas) assigned (one biotech company can be active in multiple areas). The graph displays Biotech – Therapeutics and Diagnostics subsectors as the percentage of the total number of Biotech – Therapeutics and Diagnostics subsectors with exclusion of the category “Others” or categories with a share of 2% or less. The company subsectors are regarded as the key activities of a company. For the definition of subsectors please visit www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html. Information displayed may alter as new information is received continuously.

BIOTECH - OTHER COMPANIES BY KEY ACTIVITIES

AS PERCENTAGE OF TOTAL NUMBER OF BIOTECH - OTHER COMPANIES




For 137 Biotech - Other companies there were 200 subsectors (key activity areas) assigned (one biotech company can be active in multiple areas). The graph displays Biotech - Other subsectors as the percentage of the total number of Biotech - Other subsectors with exclusion of the category Others. The company subsectors are regarded as the key activities of a company. For the definition of subsectors please visit www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html. Information displayed may alter as new information is received continuously.


BIOTECH ASSETS IN CLINICAL DEVELOPMENT

BY INDICATION AND DEVELOPMENT PHASE

BREAKDOWN BY INDICATION



BREAKDOWN BY DEVELOPMENT PHASE




Both graphs contain the number of assets of Biotech – Therapeutics and Diagnostics companies (excl. Pharma or Biotech – Others or Biotech R&D Services companies). In this analysis, development stages are shown separately, including Discovery, Lead Optimization, Preclinical, Phase I, Phase I/II, Phase II, Phase II/III, and Phase III. Information displayed in the chart may alter as new information is received continuously.


ASSETS AVAILABLE FOR OUT-LICENSING

NUMBER OF ASSETS

BY ASSET CLASS




THERAPEUTICS IN DEVELOPMENT BY DEVELOPMENT PHASE



The graph titled "Therapeutics in Development by Development Phase" displays a subset of the asset class Therapeutics. Products in Discovery and Lead Optimization Phase are merged into Preclinical; Development Phase I/II trials are merged into Phase II and Phase II/III trials are merged into Phase III category.

OVERVIEW OF OWNERSHIP


PERCENTAGE OF TOTAL NUMBER OF COMPANIES BY OWNERSHIP AND SECTOR



For the definition of categories please visit www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html. Biotech T & D stands for Biotech Therapeutics and Diagnostics. Percentage value is expressed as % of total number of companies in the sector. Information displayed may alter as new information is received continuously.

COMPANY FOUNDATION TIMELINE

NUMBER OF LIFE SCIENCE COMPANIES FOUNDED BY YEAR | 2015-2024




The graph contains the number of privately owned or publicly listed (no subsidiaries) life science companies founded by year including Biotech - Therapeutic and Diagnostic, Biotech - R&D Services, Biotech - Others, Pharma, Medical Technology and Digital Health companies. **Companies founded in 2025 were excluded** since newly founded companies often remain under the radar until their first financing round. The information displayed in the chart may alter as new information is received continuously.

VENTURE FINANCING OF LIFE SCIENCE COMPANIES

PRIVATE EQUITY ROUNDS | 2024-2025

LIFE SCIENCE COMPANIES




BIOTECH COMPANIES



Life Science companies include Biotech - Therapeutics and Diagnostics, Biotech - R&D Services, Biotech - Others, Pharma, Medical Technology and Digital Health companies. Biotech companies are a subset of Life Science companies and include: Biotech - Therapeutics and Diagnostics, Biotech - R&D Services, Biotech - Others. Financing data only includes private equity rounds (excl. private placements in public companies). Data may alter as new information is continuously received and/or new tranches to existing financing rounds are added.

BIOTECH VENTURE FINANCING

PRIVATE EQUITY ROUNDS – 5 YEAR REPORT



Biotech companies are a subset of Life Science companies and include: Biotech - Therapeutic and Diagnostic, Biotech - R&D Services, Biotech - Others. Financing data only includes private equity rounds (excl. private placements in public companies) of biotech companies (incl. therapeutic and diagnostic, R&D services and others). Data may alter as new information is continuously received and/or new tranches to existing financing rounds are added.

BIOTECH IPOs

DUTCH BIOTECH COMPANIES THAT WENT PUBLIC WORLDWIDE | 2013-2025

2021-
2025



\$328M



\$100.5M

2017-
2020



\$116.7M

2013-
2016



\$131.68M



+\$200M






\$100-200M

\$0-100M

Included are Biotech – Therapeutics and Diagnostics, Biotech – R&D Services, and Other Biotech companies.

MAJOR BIOTECH VENTURE FINANCING ROUNDS (2025)

TOP 5 DUTCH PRIVATE EQUITY FINANCING ROUNDS | 2025

Company	Sector	Type of Round	USD M
Azafaros B.V. 	Biotech – Therapeutics	Series B	\$149.36
Leyden Laboratories B.V. 	Biotech – Therapeutics	Other / unknown	\$70.00
Alesta Therapeutics 	Biotech – Therapeutics	Series A	\$67.15
Avidicure 	Biotech – Therapeutics	Seed	\$50.00
The Protein Brewery 	Biotechnology - Other	Series B	\$35.20

The table shows the five biggest private equity financing rounds (excl. IPOs, research grants, loans) of private and independent biotech companies in the Netherlands in 2025. Information displayed in the table may alter as new information is continuously received and/or new tranches to existing financing rounds are added.

MAJOR BIOTECH AND PHARMA M&A DEALS (2025)

M&A DEALS | 2025

Acquired entity	Buyer	Phase of lead asset (of acquired entity)	USD M
Merus N.V. 	Genmab A/S 	On the market	\$6900
Lava Therapeutics N.V. 	Xoma Royalty Corp 	Phase I/II	\$32.6

The table shows the M&A deals of private and independent life sciences companies in 2025. Information displayed in the table may alter as new information is continuously received and/or new tranches to existing financing rounds are added.

BENCHMARK REPORT



NETHERLANDS | FRANCE | GERMANY | UNITED KINGDOM | DENMARK | SWITZERLAND | USA



OVERVIEW OF LIFE SCIENCE COMPANIES

LIFE SCIENCE AND BIOTECH COMPANIES BY COUNTRY AND SECTOR


- ◆ USA
- ◆ Netherlands
- ◆ France
- ◆ Germany
- ◆ United Kingdom
- ◆ Denmark
- ◆ Switzerland



For the definition of categories please visit www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html. For comparison, the graph shows the rate of companies by sector per million residents of each country. Life Science companies include Biotechnology, Pharma (Fully Integrated), Medical Technology and Digital Health. Biotechnology companies are a subset of life science companies and include the following categories: Biotechnology – Therapeutics and Diagnostics; Biotechnology – R&D; Biotechnology – Other. Information displayed may alter as new information is received continuously.

OVERVIEW OF LIFE SCIENCE COMPANIES


LIFE SCIENCE COMPANIES BY COUNTRY AND SECTOR



For the definition of categories please visit www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html. For comparison, the graph shows the rate of companies by sector per million residents of each country. Biotechnology companies include the following categories: Biotechnology – Therapeutics and Diagnostics; Biotechnology – R&D; Biotechnology – Other. Information displayed may alter as new information is received continuously.

OVERVIEW OF BIOTECH COMPANIES


BIOTECH COMPANIES BY COUNTRY AND SECTOR



For the definition of categories please visit www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html. Biotech - Other includes AgBio, cosmetics, environmental, food, industrial biotechnology, nutraceuticals, and veterinary companies. For comparison, the graph shows the rate of biotech companies by subsector per million residents of each country. Information displayed may alter as new information is received continuously.

BIOTECH ASSETS IN CLINICAL DEVELOPMENT


BREAKDOWN BY TOP THREE INDICATIONS OF NETHERLANDS



The graph contains the rate of assets of Biotech – Therapeutics and Diagnostics companies per million residents of each country (excl. of Pharma or Biotech – Others or Biotech – R&D Services companies). The top three indications of the Netherlands shown are Oncology, Neurology and Infectiology/parasitology.

THERAPEUTICS BY DEVELOPMENT PHASE


PRECLINICAL AND PHASE I



The graph contains the rate of assets of Biotech – Therapeutics and Diagnostics companies per million residents of each country (excl. of Pharma or Biotech – Others or Biotech R&D Services companies). Products in Discovery and Lead Optimization Phase are merged into Preclinical. Information displayed in the chart may alter as new information is received continuously.

COMPANY FOUNDATION TIMELINE

RATE OF LIFE SCIENCE COMPANIES FOUNDED BY YEAR PER MILLION RESIDENTS | 2015-2024




The graph contains the rate of privately owned or publicly listed (no subsidiaries) life science companies founded by year per million residents of each country, including Biotech - Therapeutic and Diagnostic, Biotech - R&D Services, Biotech - Others, Pharma, Medical Technology and Digital Health companies. **Companies founded in 2025 were excluded** since newly founded companies often remain under the radar until their first financing round. Information displayed in the chart may alter as new information is received continuously.


VENTURE FINANCING OF LIFE SCIENCE COMPANIES

PRIVATE EQUITY ROUNDS OF LIFE SCIENCE COMPANIES (EUROPE AND USA) | 2024-2025

LIFE SCIENCE COMPANIES




BIOTECH COMPANIES



Life Science companies include Biotech - Therapeutics and Diagnostics, Biotech - R&D Services, Biotech - Others, Pharma, Medical Technology and Digital Health companies. Financing data only includes private equity rounds (excl. private placements in public companies). Data may alter as new information is continuously received and/or new tranches to existing financing rounds are added.

VENTURE FINANCING OF LIFE SCIENCE COMPANIES


PRIVATE EQUITY ROUNDS OF LIFE SCIENCE COMPANIES | 2024-2025



Life Science companies include Biotech - Therapeutics and Diagnostics, Biotech - R&D Services, Biotech - Others, Pharma, Medical Technology and Digital Health companies. Financing data only includes private equity rounds (excl. private placements in public companies). Data may alter as new information is continuously received and/or new tranches to existing financing rounds are added. The graph shows the benchmark countries excl. the United States.

VENTURE FINANCING OF BIOTECH COMPANIES

PRIVATE EQUITY ROUNDS OF BIOTECH COMPANIES | 2024-2025



Biotech companies are a subset of Life Science companies and include: Biotech - Therapeutics and Diagnostics, Biotech - R&D Services, Biotech - Others. Financing data only includes private equity rounds (excl. private placements in public companies). Data may alter as new information is continuously received and/or new tranches to existing financing rounds are added. The graph shows the benchmark countries excl. the United States.

MAJOR BIOTECH VENTURE FINANCING ROUNDS (2025)

TOP PRIVATE EQUITY FINANCING ROUNDS | 2025

Company	Type of Round	USD M	Country
Verdiva Bio Limited	Series A	\$410.00	United Kingdom
Tubulis GmbH	Series C	\$403.34	Germany
Windward Bio AG	Series A	\$200.00	Switzerland
Hemab Aps	Series C	\$157.00	Denmark
Artios Pharma Limited	Series D	\$151.06	United Kingdom
Azafaros B.V.	Series B	\$149.36	Netherlands
Draig Therapeutics Ltd	Series A	\$140.00	United Kingdom
GlycoEra AG	Series B	\$130.00	Switzerland
Adcytherix BV	Series A	\$123.11	France
CellCentric Ltd.	Series C	\$120.00	United Kingdom

The table shows the biggest private equity financing rounds (excl. IPOs, research grants, loans) of private and independent biotechnology – **therapeutics and diagnostics** companies in the EU and UK in 2025. Information displayed in the table may alter as new information is continuously received and/or new tranches to existing financing rounds are added. The table only shows the benchmark countries excl. the United States.

ABOUT BIOTECHGATE



Biotechgate is a leading **business development and licensing database** for the entire life science industry, offering a wealth of information on over 65,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for big pharma, start-ups, investors, and other industry professionals. Biotechgate also features 45,000 **licensing deals** and a **clinical trials database** containing over 1'000,000 records from registries around the world.

To request a free demo or to learn more about the different subscription options, please visit [Biotechgate](#).

TERMS OF USE

The Life Sciences Trend Analysis is based on data entered in the Biotechgate Database available at www.biotechgate.com. The statistics and graphs in this presentation are based on figures and information entered in this database and we do not guarantee any accuracy hereof.

The use of the figures and graphs provided in this report is free of charge for any presentations as long as www.biotechgate.com is clearly cited as the source. For all other uses please contact us for terms and conditions.



BIOTECHGATE

c/o Venture Valuation VV AG

Kasernenstrasse 11

8004 Zurich

SWITZERLAND



+41 (43) 321 86 60



www.venturevaluation.com